Financial reports
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
FibroGen Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Oct 23
8-K
Departure of Directors or Certain Officers
5 Oct 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
8-K
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
29 Aug 23
8-K
FibroGen Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
FibroGen Announces Leadership Transition
25 Jul 23
8-K
Cost Associated with Exit or Disposal Activities
19 Jul 23
8-K
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
26 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
7 Aug 23
424B5
Prospectus supplement for primary offering
27 Feb 23
S-8
Registration of securities for employees
8 Aug 22
S-3ASR
Automatic shelf registration
8 Aug 22
S-8
Registration of securities for employees
9 Aug 21
S-3ASR
Automatic shelf registration
2 Mar 20
S-8
Registration of securities for employees
9 Aug 19
424B5
Prospectus supplement for primary offering
16 Aug 17
424B5
Prospectus supplement for primary offering
15 Aug 17
424B5
Prospectus supplement for primary offering
6 Apr 17
Proxies
DEFA14A
Additional proxy soliciting materials
31 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 21
DEF 14A
Definitive proxy
13 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 19
Other
UPLOAD
Letter from SEC
3 May 22
CORRESP
Correspondence with SEC
11 Feb 22
UPLOAD
Letter from SEC
2 Feb 22
CORRESP
Correspondence with SEC
20 Jan 22
UPLOAD
Letter from SEC
5 Jan 22
CORRESP
Correspondence with SEC
16 Dec 21
UPLOAD
Letter from SEC
8 Nov 21
SEC STAFF
SEC staff action: Order
29 Mar 21
SEC STAFF
SEC staff action: Order
1 Mar 21
CT ORDER
Confidential treatment order
18 Sep 20
Ownership